Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
A phase 2 trial of Pentostatin, Rituximab and Bendamustine in Hairy cell leukaemia, run by National Cancer Institute (NCI), active and no longer recruiting.
Overview
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia is a phase 2 interventional study registered as NCT01059786 by National Cancer Institute (NCI), with 69 participants planned, started 2010-07-01 and due to reach its primary completion in 2022-12-15. Interventions recorded: Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline. Conditions recorded: Hairy Cell Leukemia.
Linked to the drug Pentostatin because the registry names it among its interventions and Hairy cell leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialFludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
Shares Pentostatin, Rituximab and the tag pipeline.
- TrialMethotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
Shares Pentostatin and the tag pipeline.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Bendamustine, Rituximab and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Bendamustine, Rituximab and the tag pipeline.
- TrialA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Shares Bendamustine, Rituximab and the tag pipeline.
- TrialA Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Shares Bendamustine, Rituximab and the tag pipeline.
- TrialA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Shares Bendamustine, Rituximab and the tag pipeline.
- TrialA Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Shares Bendamustine, Rituximab and the tag pipeline.